Enervit Logo

Enervit

ISIN

IT0004356751

Ticker

ENV

Sector

Health Care

Sub-Industry

Pharmaceuticals

Country

Italy

Year Founded

1954

About Enervit

Company Description

Positive nutrition is part of our DNA. It has always guided our advancements in field research and deepened our passion for innovation. It drives us to study the lifestyles and eating habits of the populations that have learned to live better and longer. It allows us to anticipate the nutrition of the future. It leads us to formulate and produce ideal nutrition and supplement solutions for those who practice sports, those who are health-conscious and those who want to stay in shape. All this with a specific objective: to help everyone improve the quality of their life.

For over 40 years, a passion for sports nutrition has driven our scientific research. Day after day, thanks to this unique experience we invent, test, develop and produce high-quality functional foods and innovative supplements. Ours is a fully in-house approach to satisfying the nutritional needs of those who practice sports, those who are health-conscious and those who want to stay in shape.

Headcount

232

Served Area

Worldwide

Headquarters

Viale Achille Papa 30
20149, Milano
Italy

Financial statements

Download as Excel
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Land N/A 207,243.00 207,243.00 207,243.00
Buildings N/A 3,670,780.00 3,392,353.00 3,160,431.00
Fixtures And Fittings N/A 607,355.00 580,409.00 537,446.00
Construction In Progress N/A 84,127.00 129,902.00 288,388.00
Other Property Plant And Equipment N/A 238,710.00 181,262.00 195,651.00
Brand Names N/A 60,000.00 60,000.00 60,000.00
Copyrights Patents And Other Industrial Property Rights Service And Operating Rights N/A 504,910.00 366,866.00 733,761.00
Recipes Formulae Models Designs And Prototypes N/A 990,041.00 980,362.00 939,648.00
Intangible Assets Under Development N/A 390,898.00 604,265.00 223,644.00
Other Intangible Assets N/A 24,686.00 20,059.00 15,432.00
Trade And Other Current Receivables Due From Related Parties N/A 535,252.00 701,382.00 965,976.00
Cash and cash equivalents 2,379,133.00 13,948,134.00 18,504,912.00 16,757,494.00
Statutory Reserve N/A 1,236,405.00 1,236,405.00 1,413,917.00
Capital Reserve N/A 46,481.00 46,481.00 46,481.00
Noncurrent Derivative Financial Liabilities N/A 216,682.00 62,290.00 0.00
Longterm Borrowings N/A 20,968,705.00 16,782,984.00 12,799,430.00
Line item in (eur) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue From Contracts With Customers 51,836,625.00 64,749,977.00 76,304,783.00
Profit (loss) -1,898,499.00 3,595,539.00 4,164,907.00
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A -1,898,499.00 3,595,539.00 4,164,907.00
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes N/A 11,569,002.00 4,556,778.00 -1,747,418.00
Cash and cash equivalents 2,379,133.00 13,948,134.00 18,504,912.00 16,757,494.00

Please note that some sums might not add up.

Filings & Publications

  • Consolidated Report 2022 - Q4 Italian 🇮🇹 Published: 30.05.2023
  • Consolidated Report 2021 - Q4 Italian 🇮🇹 Published: 30.05.2023

Capital Markets Information

ISIN

IT0004356751

LEI

8156002B06C3A4C0F436

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

Borsa Italiana

Contact Investor Relations Department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.